Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

Open access
Gadgeel, Shirish M., Pennell, Nathan A., Fidler, Mary Jo, Halmos, Balazs, Bonomi, Philip, Stevenson, James, Schneider, Bryan, Sukari, Ammar, Ventimiglia, Jaclyn, Chen, Wei, Galasso, Cathy, Wozniak, Antoinette, Boerner, Julie, Kalemkerian, Gregory P.·2018·Journal of Thoracic Oncology

Abstract

Objective: The aim of this study was to assess the efficacy of maintenance pembrolizumab in patients with extensive‐stage SCLC after treatment with platinum and etoposide. Methods: Patients with extensive‐stage SCLC with a response or stable disease after induction chemotherapy were eligible. Pembrolizumab at a dose of 200 mg administered intravenously every 3 weeks was initiated within 8 weeks of the last cycle of chemotherapy. The primary end point of the study was progression‐free survival (PFS) from study registration, with overall survival (OS) as a key secondary end point. Available tumor tissue was assessed for expression of programmed death ligand 1 (PD‐L1) both in the tumor cells and in the surrounding stroma. Blood for circulating tumor cells was collected before the first, second, and third cycles of pembrolizumab. Results: Of the 45 patients enrolled, 56% were male and 22% had treated brain metastases. The median PFS was 1.4 months (95% confidence interval [CI]: 1.3–2.8), with a 1‐year PFS of 13%. The median OS was 9.6 months (95% CI: 7.0–12), with a 1‐year OS of 37%. Of the 30 tumors that could be assessed, three had PD‐L1 expression (≥1%) in the tumor cells. A total of 20 tumors could be assessed for PD‐L1 expression in the stroma. The median PFS in the eight patients with tumors positive for expression of PD‐L1 at the stromal interface was 6.5 months (95% CI: 1.1–12.8) compared with 1.3 months (95% CI: 0.6–2.5) in 12 patients with tumors negative for this marker. No unexpected toxicities were observed. Conclusion: Maintenance pembrolizumab did not appear to improve median PFS compared with the historical data. However, the 1‐year PFS rate of 13% and OS rate of 37% suggest that a subset of patients did benefit from pembrolizumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.05.002

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 212

Metadata

Authors
Gadgeel, S. M., Pennell, N. A., Fidler, M. J., Halmos, B., Bonomi, P., Stevenson, J., Schneider, B., Sukari, A., Ventimiglia, J., Chen, W., Galasso, C., Wozniak, A., Boerner, J., & Kalemkerian, G. P.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2018-09
Volume
13
Issue
9
Pages
1393-1399
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2804287047
Cited by
212
References
3
FWCI
11.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). https://app.cochat.ai/papers/10.1016/j.jtho.2018.05.002
The paper
Gadgeel, S. M., Pennell, N. A., Fidler, M. J., Halmos, B., Bonomi, P., Stevenson, J., Schneider, B., Sukari, A., Ventimiglia, J., Chen, W., Galasso, C., Wozniak, A., Boerner, J., & Kalemkerian, G. P. (2018). Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.05.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.